金吾财讯 | 诺和诺德（NVO）与AI初创公司Anthropic联合宣布达成战略合作。诺和诺德将引入Anthropic旗下的前沿大模型（包括Claude Science），应用于新药研发与智能软件工程，以加速创新药物的发现进程。根据合作协议，双方将重点针对生物学推理及复杂计算难题开展联合攻关。诺和诺德计划率先在特定的研发工作流程中试点测试Claude Science，借此缩短从基础研究到药物上市的周期。此外，诺和诺德还将利用前沿模型强化内部软件开发能力，为AI技术在全公司的规模化应用提供支撑。诺和诺德首席执行官Mike Doustdar表示，此次合作旨在巩固公司成为“全球最具AI驱动力医疗企业”的战略目标，通过AI深入探索人类生物学机制与药物作用原理。Anthropic联合创始人兼CEO Dario Amodei则指出，顶级安全模型的引入有望大幅压缩生物医药突破的时间轴。据悉，整项合作将在既定的数据治理框架与人工监督下运行，以确保符合行业合规与伦理标准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.